BUY $CUE
BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will host a conference call and webcast to provide a business and clinical update on Thursday, November 9, 2023 at 4:30 p.m. ET. Live and archived versions of the event can be accessed via the Company’s website.
The Company will provide a clinical update from its Phase 1 trials evaluating the lead interleukin 2 (IL-2)-based biologic, CUE-101, as monotherapy and in combination with KEYTRUDA® (pembrolizumab) for patients with recurrent/metastatic HPV+ head and neck cancer and from the ongoing Phase 1 trial with the Company’s second IL-2 based candidate, CUE-102, for the treatment of Wilms’ Tumor 1 (WT1) expressing cancers. Additional clinical, pipeline and business updates will also be addressed.
As a reminder, posters highlighting new positive data from the CUE-101 and CUE-102 clinical programs will be presented at the Society for Immunotherapy of Cancer’s 38th Anniversary Annual Meeting (SITC 2023) on November 4, 2023.
Webcast Details
Thursday, November 9 at 4:30 p.m. ET
| Investors: | 1-888-886-7786 | |
| International Investors: | 1-416-764-8658 | |
| Conference ID: | 38547752 | |
| Request a return call via the Call me™ link: | https://emportal.ink/3RIYunz | |
| Participants can use guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The link will be active 15 minutes prior to the scheduled start time. | ||
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1638430&tp_key=eaa2024234 | |
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the body’s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Maya Romanchuk
LifeSci Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
BUY $CUE
| Last Trade: | US$1.10 |
| Daily Change: | -0.15 -11.65 |
| Daily Volume: | 463,863 |
| Market Cap: | US$53.500M |
November 14, 2024 November 14, 2024 November 12, 2024 October 04, 2024 | |
BUY $CUE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE